

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: April 14, 2015**

**Commission File Number: 001-36891**

---

**Collectis S.A.**

(Exact Name of registrant as specified in its charter)

---

**8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Title</u></b>
99.1	Press release, dated April 14, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**  
(Registrant)

April 14, 2015

By: /s/ André Choulika  
André Choulika  
Chief Executive Officer

PRESS RELEASE

**Cellecctis Plant Sciences, Inc. Publishes a Study Demonstrating  
Reduced Acrylamide in Fried Potatoes**

**April 14, 2015** — New Brighton (Minnesota, USA) — Cellecctis Plant Sciences, Inc. a Minnesota-based company focusing on developing healthier food products, has announced today that the Plant Biotechnology Journal has accepted the publication of its peer-reviewed manuscript demonstrating the phenotypic validation of potato lines developed by inactivating a single endogenous gene responsible for sugar accumulation when stored at cold temperatures.

The non-transgenic product has already received an approval from the USDA to be grown in fields. The field trial will start this spring to obtain commercial proof of concept of large-scale cold storability and reduced acrylamide content for French fries, potato chips and fresh-cut applications.

“We firmly believe that the new product developed by our team opens the path to the future of food products,” commented Luc Mathis, Chief Executive Officer of Cellecctis Plant Sciences. “Consumers want access to higher quality products developed without using unhealthy chemicals that are currently used to avoid sprouting of potatoes stored at room temperature. The reduction in fried products of the potentially carcinogenic compound acrylamide will bring additional benefits to consumers.”

**Plant Biotechnology Journal**

**Improving cold storage and processing traits in potato through targeted gene knockout**

Benjamin M. Clasen, Thomas J. Stoddard, Song Luo, Zachary L. Demorest, Jin Li, Frederic Cedrone, Redeat Tibebe, Shawn Davison, Erin E. Ray, Aurelie Daulhac, Andrew Coffman, Ann Yabandith, Adam Retterath, William Haun, Nicholas J. Baltus, Luc Mathis, Daniel F. Voytas and Feng Zhang

Article first published online: April 7, 2015

DOI: 10.1111/pbi.12370

**For further information, please contact:**

**Media contacts**

Jennifer Moore, Director of Communications

Phone: 917-580-1088

email: [contact@cellectis-plantsciences.com](mailto:contact@cellectis-plantsciences.com)



**BMC Communications - New York City**

Brad Miles  
Phone: 646-513-3125  
email: [bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)

**IR contacts**

Simon Harnest, VP Finance and Investor Relations  
Phone: 646-385-9008  
email: [simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)

**About Collectis Plant Sciences**

Founded in 2010, Collectis Plant Sciences is based in New Brighton, Minnesota (United States). The company has developed a platform to improve the quality of crops for the food and agriculture industries. Collectis Plant Sciences is involved in a network of collaborations that include global companies (Bayer, Limagrain, Monsanto, and SESVanderhave, among others), as well as leading healthcare (Mitsubishi Tanabe Pharma) and food companies. Collectis Plant Sciences is developing innovative products with prominent partners in order to secure accessibility of its products to consumers.

For further information please visit our website: [www.collectis-plantsciences.com](http://www.collectis-plantsciences.com)

**Disclaimer**

This press release contains forward-looking statements. You should not place undue reliance on such statements because they are subject to numerous risks and uncertainties relating to the company's operations and business environment, all of which are difficult to predict and many are beyond the company's control. Forward-looking statements include information concerning the company's possible or assumed future results of operations, including descriptions of its business strategy. These statements often include words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or similar expressions. These factors are more fully discussed in the "Risk Factors" section and elsewhere in the company's Registration Statement on Form F-1, as amended (File No. 333-202205). You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although the company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual financial results or results of operations and could cause actual results to differ materially from those in these forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.